ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LY3981314

A development code.

Its studies are mostly in Hepatitis, led by Eli Lilly.

Furthest: phase 1, since Jun 3, 20252 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly22 open or runningphase 1since Jun 3, 2025Jun 3, 2025Feb 2027phase 1 · NCT07005284

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2025First study: phase 1 study in HealthyFirst studyNCT07005284 · 76 enrolled · United States
  2. Nov 5, 2026Phase 1 study in HepatitisNCT07928219 · 12 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 1 study in HealthyNCT07005284
  2. Jun 2028Primary completion: phase 1 study in HepatitisNCT07928219

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07928219Hepatitis · United States1Not yet recruitingJun 202812
NCT07005284Healthy · United States1Active, not recruitingFeb 202776

How it is read

Names in the registry

  • “LY3981314”, 2 entries

Codes read as this program: LY3981314.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.